The decision by Basilea to focus on its well-established anti-infectives franchise at the expense of its nascent oncology pipeline has...

The announcement this morning that Basilea has sold one of its preclinical oncology programmes reflects its determination to focus and...

Basilea announced this morning that it has secured non-dilutive financing to help repay the outstanding CHF117m of December 2022...